Showing results (31-40 of 90) with videos related to
Sort By:
Pageof 9
Oncotarget|October 6, 2017
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activationStefania Napolitano, Giulia Martini, Erika Martinelli, et al.Expert Review of Molecular Diagnostics|June 20, 2020
Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an updateIosune Baraibar, Javier Ros, Nuria Mulet, et al.Therapeutic Advances in Medical Oncology|March 22, 2021
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancerJavier Ros, Iosune Baraibar, Emilia Sardo, et al.Therapeutic Advances in Medical Oncology|August 13, 2020
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancerGiulia Martini, Rodrigo Dienstmann, Javier Ros, et al.Clinical Colorectal Cancer|February 1, 2022
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survivalDavide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, et al.Frontiers in Oncology|March 2, 2023
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trialGiulia Martini, Davide Ciardiello, Stefania Napolitano, et al.Critical Reviews in Oncology/Hematology|November 21, 2021
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?Amelia Insa, Paloma Martín-Martorell, Raimondo Di Liello, et al.Journal of Alzheimer'S Disease : JAD|March 31, 2015
Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer's Disease Patients as a Potential Protective Mechanism against Neurodegenerative DeclineClaudia Altamura, Mariacarla Ventriglia, Maria Giulia Martini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2015
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with CetuximabStefania Napolitano, Giulia Martini, Barbara Rinaldi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2015
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft ModelsTeresa Troiani, Stefania Napolitano, Giulia Martini, et al.Pageof 9